Colin Mcbride

RiverGlade Capital is a private equity firm focused on control buyouts of growth-oriented, lower middle market healthcare companies. Through partnership with founder-owned, high-quality, differentiated businesses, RiverGlade strives to accelerate value, professionalize, and transform organizations into highly attractive strategic assets. Founded in 2017, RiverGlade’s Managing Partners have been investing together for more than two decades, and bring the resources, relationships, and validated methodologies to help scale exceptional healthcare companies. Investment Focus RiverGlade partners with founder-owned healthcare businesses that have proven organic growth, multiple levers for value-creation, a culture of compliance and clinical excellence, and a differentiated service offering with a strong market reputation. Companies typically have more than $3 million in EBITDA and align with RiverGlade’s operating resources and expertise. RiverGlade generally looks to invest $20-80 million of equity per platform in transactions with meaningful founder rollover and a prudent leverage structure. RiverGlade has consistently utilized a macro theme-driven, top-down approach to identify areas of the healthcare sector that may present actionable opportunities. Currently, RiverGlade is focused on compelling opportunities within 1) multi-unit, 2) outsourced services, 3) tech-enabled solutions, and 4) medical products and distribution models.